Modular Medical (NASDAQ:MODD) announced successful results from its pre-clinical GLP-1 proof of concept study. The study demonstrated enhanced weight loss and blood glucose control using a pump-delivered rapid-acting GLP-1 with both basal and bolus dosing. The highest basal-bolus dose achieved 17.1% weight loss at 28 days, compared to 13.7% with basal alone. All dosing variations outperformed semaglutide in glucose control. The study involved 5 treatment arms, with semaglutide showing 24.9% weight loss but with a sharp 8% drop in the first two days. The company plans to advance this basal-bolus GLP-1 concept to human trials using their MODD1 device.